Swiss excellence: Unlocking the secrets of Basel’s unique healthtech innovation ecosystem

A recurring theme was that Basel compresses the essential ingredients of healthtech into a small geography. This density is one of the defining features of the Basel Area Life Sciences Supercluster: from pharma to clinical care to academia, the distance to collaboration is short.

As Astrid Kiermaier put it, “in the healthcare ecosystem … we have in a very close proximity every player around, and it’s easy to connect.” Bram Stieltjes described arriving in Basel and seeing “the hospital, two big pharma companies … all in such a small place.”

Basel also benefits from being a trinational region with natural connectivity across borders, which expands the partner and talent surface area beyond city limits.

The discussion emphasized that collaboration is not an ecosystem nice-to-have – it is a requirement driven by how modern pharma innovation works.

Astrid Kiermaier highlighted that clinical trials generate only a small slice of the data needed for a comprehensive patient picture. If you want to understand patients holistically, you must learn from the much larger share of patients who are not in trials and the data that sits outside trial datasets.

This is where the structure of the Basel Supercluster matters. Collaboration happens across pharma, hospitals, startups and the public sector because proximity makes it easier to align around shared problems, not only shared events.

Basel’s healthtech opportunity is tightly linked to a shift in what “infrastructure” means. Buildings and labs still matter, but the panel argued that data frameworks and standards will increasingly determine the speed at which innovation can move.

A practical example is University Hospital Basel’s move toward openEHR, an open standard that enables structured clinical data capture and reuse.

Bram Stieltjes framed this as ecosystem design, not just a technical upgrade: creating a foundation that supports a regional health data environment, not a single institution’s database. He stressed that “a hospital alone is not good enough. You need to have data on a regional basis.” He also highlighted why openness matters: if software providers sit in the middle, they can control data definitions and access, centralizing power and reducing collaboration. Open standards help avoid that dynamic.

Basel’s advantage is not only that stakeholders want to collaborate. It is that they are actively working to remove the operational friction that makes collaboration hard at scale.

One challenge discussed is the request cycle problem: repeated back and forth to find out whether relevant patient cohorts exist, how many there are, or whether a hypothesis is feasible. Bram Stieltjes described why this does not scale if every enquiry requires manual processing.

The direction described is to enable more self-service feasibility exploration, so users can explore parameters without exposing patient-level data. Astrid Kiermaier also pointed to privacy preserving approaches such as synthetic data as one way to reduce governance overhead and cut rounds of paperwork that slow collaboration.

A key forward-looking note from Astrid Kiermaier was that constraints on medical data use are likely to increase, making it even more important to invest in ways of working that enable innovation under tighter rules, rather than defaulting to slower contracting cycles.

The canton’s role was framed as enabling conditions: infrastructure, innovation promotion programs and legal frameworks that make collaboration easier and keep the region competitive.

Karin Sartorius described Basel-Stadt’s latest response to increased global competition: the creation of the Basel Incentive Programme, also referred to as the Basler-Standortpaket, with up to CHF 400m annual resources allocated to support spending for R&D and high-tech production in Basel-Stadt companies.

She also pointed to a specific gap many ecosystems struggle with: funding mechanisms that directly encourage collaboration between startups, hospitals, universities and industry. Basel is explicitly planning support in this direction effective from late 2026.

The audience Q&A sharpened the future agenda. A recurring question was whether Switzerland’s federal structure creates inevitable fragmentation for health data and research collaboration. The response was nuanced: federalism does not have to mean a fragmented data space if standards and intent are aligned.

Two constraints stood out. First is standardization and harmonization: the more clinical and research participation models can be standardized, the less organizations need to navigate “20 different” approaches. Second is willingness to share: progress depends on shared intent, clear benefits and mechanisms that make collaboration feel safe and worthwhile.

Beyond Switzerland, the panel also pointed to emerging requirements for understanding the full patient journey. Astrid Kiermaier noted that this often starts with registries and cohorts, with approaches like tokenization offering potential but facing regulatory and legislative hurdles in Europe.

Basel’s story is not that the region has “lots going on.” It is that the ecosystem has built a practical advantage by reducing the distance between discovery, clinical reality, industry capability and public sector enablement. For pharma innovation leaders, that density is valuable because it makes collaboration easier to initiate, easier to govern and more likely to translate into outcomes.

The panel’s most consistent message is that modern innovation depends on combining complementary capabilities and datasets. In practice, that means building partnership models that can connect clinical trial insights with real-world clinical data, while staying compliant and earning trust. Basel’s trajectory is also a reminder that infrastructure is increasingly defined by data standards and interoperable foundations. Open approaches like openEHR matter because they reduce lock-in, encourage reuse and make it more feasible to think beyond single-institution datasets.

Finally, the discussion highlighted that ecosystem competitiveness is not only a private sector concern. Policy tools such as the Basel innovation promotion programs and the Basel Incentive Programme, plus targeted support for collaboration, can create the conditions for faster experimentation, stronger partnerships and long-term resilience in the face of tightening constraints around medical data use.

Visit our Contact us page and tell us what you are trying to achieve via the form. Whether you are exploring innovation partnerships, looking for validation environments, or assessing where to build your next healthtech initiative, the DayOne team will follow up with relevant pathways and connections.